Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JNJ-77242113 in Healthy Chinese Adults
NCT05703841Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of icotrokinra in plaque psoriasis (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Area Under the Plasma Concentration versus Time Curve From Time Zero to Time of the Last Measurable Concentration, Area Under the Plasma Concentration versus Time Curve From Time Zero to Infinite Time and 5 more. Started Feb 2023; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05703841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703841.